Orthocell Limited announce it has appointed Samson Medical Technologies ("SMT") as its exclusive distributor of Striate+™ (CelGro® Dental) for bone and soft tissue repair across the Australia. Samson Medical Technologies appointed as exclusive distributor in Australia of Orthocell's Striate+™ (CelGro® Dental) product for bone and soft tissue repair; Samson Medical Technologies has established relationships with leading dental surgeons and an experienced sales team throughout Australia; Exclusive distributor focused on growing network of product users through targeted promotion and education activities; Striate+™ is well positioned to gain traction in Australia with Samson Medical Technologies as Orthocell expands into the US, the healthcare market. The distributor agreement follows inclusion of Striate+™ on the Australian Prostheses List. Inclusion on the Prostheses List enables dental practitioners to receive reimbursement from private insurers for use of Striate+TM in approved dental bone and soft tissue repair procedures, reducing costs to the patient. SMT will distribute Striate+™ for use in bone and soft tissue repair across Australia undertaking targeted promotion activities, initiating sales, as well as expanding the network of referring periodontists and oral and maxillofacial surgeons. The exclusive distribution agreement has a term of five years and enables Orthocell access to this strategic market, with a growing uptake of Australian made high quality products. With a panel of experts and now a distributor in place, Orthocell is well positioned to gain market traction in Australia, as it works to expand into the US, the healthcare market and establish Striate+™ as the high quality collagen membrane for oral bone and soft tissue regeneration procedures.